Valuation: Verastem, Inc.

Market Cap 663M 577M 546M 497M 928M 63.49B 932M 6.51B 2.52B 32.27B 2.49B 2.43B 103B P/E 2026 *
-4.47x
P/E 2027 * -6.28x
Enterprise Value 705M 614M 581M 528M 986M 67.5B 991M 6.92B 2.68B 34.31B 2.65B 2.59B 110B EV / Sales 2026 *
6.05x
EV / Sales 2027 * 3.66x
Free-Float
98.98%
Yield 2026 *
-
Yield 2027 * -
1 day+3.14%
1 week-0.92%
Current month+4.57%
1 month+5.15%
3 months+81.06%
6 months+33.16%
Current year-2.20%
1 week 7.2
Extreme 7.195
7.91
1 month 6.62
Extreme 6.62
8.54
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
10.82
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap. Importance
3/8/26 Sell

Chief Executive Officer

-1,302 0.0021%
21/5/26 Free

Director

108,000 0.1229%
21/5/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
+3.14%-0.92%-20.02%-23.74% 663M
+1.76%+3.62%+49.92%+101.12% 69.69B
+2.29%+0.32%+37.65%+77.03% 61.24B
+1.14%-2.59%-14.37%+366.97% 26.77B
+0.32%+2.58%+29.26%+14.12% 26.12B
+2.95%+2.34%+0.52%-9.52% 24.07B
+1.49%+5.15%+26.46%-15.89% 20.39B
-0.83%-11.15%+169.70%+295.44% 15.72B
+3.01%+1.85%+44.63%+173.96% 14.07B
+0.17%-4.07%-9.71%+484.05% 14.03B
Average +1.54%-1.85%+31.40%+146.35% 27.28B
Weighted average by Cap. +1.60%+0.18%+36.16%+129.31%

Financials

2026 *2027 *
Net sales 116M 101M 95.99M 87.21M 163M 11.15B 164M 1.14B 442M 5.67B 437M 428M 18.14B 181M 158M 149M 136M 253M 17.35B 255M 1.78B 688M 8.82B 680M 665M 28.22B
Net income -166M -144M -137M -124M -232M -15.89B -233M -1.63B -630M -8.07B -623M -609M -25.85B -157M -137M -129M -118M -220M -15.04B -221M -1.54B -596M -7.64B -590M -577M -24.47B
Net Debt 41.9M 36.49M 34.54M 31.38M 58.63M 4.01B 58.92M 411M 159M 2.04B 157M 154M 6.53B -
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
18/09/26 US$7.550 +3.14% 1,733,761
16/09/26 US$7.320 -0.27% 1,452,334
15/09/26 US$7.340 -2.26% 2,840,151
14/09/26 US$7.510 +2.60% 1,514,530
11/09/26 US$7.320 -3.94% 1,913,863
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
7.320USD
Average target price
14.67USD
Spread / Average Target
+100.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!